Compare Amgen, Inc. (AMGN) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Synchrony Financial — how do they compare? Amgen, Inc. trades at $417.62 (market cap $224.14B), while Synchrony Financial trades at $78.75 (market cap $25.53B). The key difference: Amgen, Inc. is far larger — about 8.8× Synchrony Financial's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | SYF | |
|---|---|---|
Market Cap | $224.14B | $25.53B |
Sector | Health | Financials |
52-Week High | $417.20 | $88.47 |
52-Week Low | $271.18 | $63.78 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Synchrony Financial (SYF) trades at $78.25, up 0.08% on the day, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The stock shows robust fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent revenue around $15.0B. Recent news highlights partnerships like CareCredit with Stripe and aggressive share buybacks, while analyst consensus is strongly positive with a $86.33 price target.
The outlook for SYF is favorable due to undervaluation, earnings growth, and shareholder returns via dividends and buybacks. Risks include economic sensitivity to consumer spending and rising expenses. With no sell ratings from analysts and institutional confidence, the stock presents a solid opportunity for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
